
SCSB Lunch Series with Dr. Tatsuya Osaki: Modeling Blood-Brain Barrier Integrity and Hemodynamics in Autism Spectrum Disorder with an iPSC-Derived Microphysiological System
Downloads an .ics file · Times are in America/New_York · Google Calendar
Date: Friday, October 16, 2026 Time: 12:00pm – 1:00pm Location: Simons Center Conference room 46-6011. Zoom: https://mit.zoom.us/j/99705232954 Speaker: Tatsuya Osaki, Ph.D. Affiliation: Research Scientist, Mriganka Sur Laboratory, Picower Institute for Learning and Memory, MIT Talk title: Modeling Blood-Brain Barrier Integrity and Hemodynamics in Autism Spectrum Disorder with an iPSC-Derived Microphysiological System Abstract: Autism spectrum disorder (ASD) encompasses a diverse group of neurodevelopmental conditions characterized by challenges in social interaction, cognition, and communication. While neuronal dysfunction has been extensively studied, the role of vascular dysregulation, particularly blood-brain barrier (BBB) integrity and cerebrovascular hemodynamics during early development, remains largely unexplored. Using Rett syndrome (RTT) as a disease entry point, we demonstrate that mutations in methyl-CpG binding protein 2 (MeCP2) impair endothelial cell function, suggesting a vascular-intrinsic contribution to pathogenesis. To investigate this, we developed a human iPSC-derived microphysiological system recapitulating BBB structure and function in a physiologically relevant 3D environment. Patient-derived endothelial cells carrying MeCP2 mutations self-assembled into perfusable microvascular networks, revealing significant impairment in vascular barrier function, independently validated in MeCP2 knockout mouse models. Transcriptomic analysis identified aberrant upregulation of miR-126 and loss of tight junction integrity as key mediators of BBB dysfunction. Targeted inhibition of miR-126-3p restored barrier function, establishing it as a novel therapeutic candidate. Building on these findings, we are expanding this platform to model hemodynamic alterations across broader ASD subtypes, with in vivo cross-validation via two-photon microscopy, aiming to uncover shared neurovascular mechanisms and identify therapeutic targets for ASD and related neurodevelopmental disorders.
More like this near Boston
Going to SCSB Lunch Series with Dr. Tatsuya Osaki? Ask me anything about it.
I read the organiser's pages and answer in a few seconds.
Answers are AI-generated · Privacy



